科创板上市公司 独立董事提名人声明与承诺 提名人湖北华强科技股份有限公司董事会,现提名刘景伟为湖北 华强科技股份有限公司第二届董事会独立董事候选人,并已充分了解 被提名人职业、学历、职称、详细的工作经历、全部兼职、有无重大 失信等不良记录等情况。被提名人已书面同意出任湖北华强科技股份 有限公司第二届董事会独立董事候选人(参见该独立董事候选人声 明)。提名人认为,被提名人具备独立董事任职资格,与湖北华强科 技股份有限公司之间不存在任何影响其独立性的关系,具体声明并承 诺如下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、规章及其他规范性文件,具有五年以上法律、经济、会计、 财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求: (一)《中华人民共和国公司法》等关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定; (三)中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定; ( ...

根据《中华人民共和国公司法》(以下称"《公司法》")、《中华人民共和国证 券法》、《上海证券交易所科创板股票上市规则》、《上市公司独立董事管理办法》 等法律法规及《公司章程》的相关规定,我们作为湖北华强科技股份有限公司(以 下简称"公司")的独立董事,对公司第一届董事会第二十七次会议(以下简称 "本次会议")相关事项发表事前认可意见如下: 一、《关于聘请 2023年度审计机构的议案》 经事前审核,我们认为:天职国际会计师事务所(特殊普通合伙)具有从事 证券、期货业务相关执业资格,其审计团队敬业谨慎,具备为上市公司提供审计 服务的经验与能力,能够为公司提供真实公允的审计服务,具备足够的独立性、 专业胜任能力、投资者保护能力,满足公司 2023年度审计工作的要求。公司已 就变更会计师事务所的相关事项提前与原审计机构大信会计师事务所(特殊普通 合伙)进行了沟通,其已对该事项进行确认且无异议。因此,我们同意聘任天职 国际会计师事务所(特殊普通合伙)为公司 2023年度财务报告和内部控制审计 机构,并同意将该议案提交公司第一届董事会第二十七次会议审议。 (以下无正文) 独立董事:王广昌、刘洪川、刘景伟 2023 年 1 ...

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司2023年半年度持续督导跟 踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：华强科技 | | --- | --- | | 保荐代表人姓名：刘伟 | 联系电话：021-38966588 | | 保荐代表人姓名：张展培 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为湖北华强科技股份有限公司（以 下简称"华强科技"、"公司"或"发行人"）首次公开发行股票并在科创板上市 项目的保荐机构，对华强科技进行持续督导，并出具 2023 年半年度（以下简称 "本报告期"或"报告期"）持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 报告期内，公司存在使用闲置募集资金进行现金管理的合计余额超过董事会 授权额度的情况。因公司对通知存款的理解存在偏差，以及相关工作人员工作失 误等原因，导致公司在 2022 年 1 月 29 日至 2023 年 7 月 28 日之间的 ...

特此公告。 湖北华强科技股份有限公司董事会 2023 年 9 月 13 日 1 证券代码：688151 证券简称：华强科技 公告编号：2023-034 湖北华强科技股份有限公司 关于董事会、监事会延期换届的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖北华强科技股份有限公司（以下简称"公司"）第一届董事会、监事会于 2023 年 9 月 14 日任期届满。鉴于公司新一届董事会、监事会候选人的提名工作 尚在积极推进中，为保证公司董事会、监事会相关工作的连续性和稳定性，公司 第一届董事会、监事会将延期换届。同时，公司董事会各专门委员会及董事会聘 任的高级管理人员的任期亦相应顺延。 在公司新一届董事会、监事会换届选举工作完成前，公司第一届董事会、监 事会、董事会各专门委员会成员及高级管理人员将按照相关法律法规和《公司章 程》等有关规定，继续履行董事、监事及高级管理人员的职责和义务。 公司董事会、监事会延期换届不会影响公司的正常运营。公司将积极推进相 关工作，尽快完成董事会、监事会的换届选举工作，并及时履行信息披露 ...

证券代码：688151 证券简称：华强科技 公告编号：2023-033 湖北华强科技股份有限公司 关于上海证券交易所对公司及有关责任人予以监管 警示的整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖北华强科技股份有限公司（以下简称"华强科技"或"公司"）于 2023 年 8 月 14 日收到上海证券交易所科创板公司管理部发送的《关于对湖北华强科 技股份有限公司及有关责任人予以监管警示的决定》（上证科创公监函 [2023]0042 号，以下简称"《决定书》"）。公司收到《决定书》后，对提出 的问题高度重视，及时向公司全体董事、监事、高级管理人员及相关部门人员进 行了通报，并召集公司管理层及相关部门按照《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司信息披露管理办法》《上海证券交易所科创板股 票上市规则》等法律、法规和规范性文件的规定，对《决定书》中涉及的问题进 行了分析研讨和全面自查，并深刻反思公司在信息披露和规范运作等方面存在的 问题和不足，认真整改，举一反三，杜绝此类问题的再次发生。现将公司具体整 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[16]. - The company's operating revenue for the first half of 2023 was ¥268,432,420.73, a decrease of 21.77% compared to ¥343,119,450.71 in the same period last year[23]. - Net profit attributable to shareholders decreased by 69.73% to ¥28,972,802.36 from ¥95,699,794.66 year-on-year[23]. - The basic earnings per share dropped by 71.43% to ¥0.08 from ¥0.28 in the previous year[25]. - The gross profit margin for the first half of 2023 improved to 40%, up from 35% in the same period last year[16]. - The gross profit margin for the main business was 17.77%, a decrease of 11.23 percentage points year-on-year[77]. - The company faced a negative operating cash flow of CNY -137.34 million due to delayed payments from military and major clients[72]. - The company's cash flow from operating activities showed a net outflow of ¥137,337,559.06, compared to an outflow of ¥130,300,408.63 in the same period last year[23]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% compared to the first half[16]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish two new distribution centers by the end of 2023[16]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance market share by 10%[16]. - Future guidance includes a target of reaching RMB 1 billion in total revenue by the end of 2024, with a focus on sustainable growth strategies[16]. - The company aims to leverage its technological advantages to expand into the medical packaging and medical device markets[32]. Research and Development - The company has invested RMB 50 million in R&D for advanced protective technologies, aiming to improve product efficiency by 30%[16]. - The company completed 6 patent applications and obtained 10 new patents during the reporting period, bringing the total number of effective authorized patents to 175[42]. - Total R&D investment decreased by 34.76% year-on-year to approximately 22.64 million yuan, accounting for 8.43% of operating revenue[44]. - The company has established a new R&D center in Beijing to enhance its innovation capabilities and support future equipment development and production[35]. - The company is focusing on core technologies in special protection and medical packaging, with 15 core technologies identified for development[41]. Environmental Compliance - The company has implemented measures to ensure pollutant emissions meet national and local standards, with no exceedances reported[99]. - The company has established an environmental protection mechanism to comply with relevant regulations[97]. - The company has received environmental approval for its new filter production line project, with approval number 宜高环审【2023】18号[104]. - The company is committed to adhering to the GB27632-2011 and GB14554-93 emission standards across its operations[100][101]. - The company has conducted environmental monitoring, with all indicators meeting national standards as per the wastewater monitoring requirements[107]. Shareholder Commitments and Governance - The company’s controlling shareholder, the Equipment Group, has committed to a 36-month lock-up period for shares post-IPO, prohibiting any transfer or management delegation of shares held prior to the IPO[117]. - The company has established measures to resolve related party transactions and competition issues with its controlling shareholder[116]. - The company has received commitments from all directors and senior management to adhere to long-term shareholding restrictions[115]. - The company will ensure compliance with all regulatory requirements regarding share transfers[126]. - The company will publicly disclose reasons for any unfulfilled commitments and apologize to shareholders and the public[161]. Investment and Financial Management - The total amount of raised funds is CNY 3,024,975,558, with a net amount of CNY 2,812,150,820 after deducting issuance costs[180]. - The company has approved the use of up to RMB 190 million of temporarily idle raised funds for cash management, with a validity period of 12 months from the board's approval date[188]. - The company is exploring additional funding sources to support ongoing and future projects, ensuring sustainable growth[184]. - The company has reported a 100% utilization rate of the funds allocated for debt repayment, indicating effective financial management[184]. - The company plans to optimize its project management and resource allocation to mitigate investment risks[181].

湖北华强科技股份有限公司 关于参加2023 年半年度医疗器械及医疗设备行业集体业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 9 月 5 日（星期二）下午 13:00-15:00 证券代码：688151 证券简称：华强科技 公告编号： 2023-028 会议召开方式：网络文字互动 网 络 文 字 互 动 平 台 ： 上 海 证 券 交易所上证路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 4 日（星期一）16:00 前通过邮件、电话、传真等 形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 湖北华强科技股份有限公司（以下简称"公司"）将于 2023 年 8 月 31 日披露 公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 年半年度医疗 器械及 ...

证券代码：688151 证券简称：华强科技 公告编号： 2023-027 湖北华强科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 08 月 31 日(星期四) 下午 14:00-15:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 24 日(星期四) 至 08 月 30 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （office@hqtc.com）进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖北华强科技股份有限 ...

经查明，湖北华强科技股份有限公司（以下简称公司）2022 年 度使用闲置募集资金购买结构性存款获取的投资收益为 2,018.94 万 元。公司于 2023 年 4 月 21 日披露的 2022 年年度报告中，将前述投 资收益认定为经常性损益。2023 年 7 月 18 日，公司披露《关于 2022 年年度报告以及非经常性损益披露差错的补充及更正公告》，将购 买结构性存款获取的投资收益调整认定为非经常性损益,据此对公 司 2022 年年度报告进行更正。其中，2022 年归属于上市公司股东 的扣除非经常性损益的净利润（以下简称扣非归母净利润）由 860.19 万元更正为-855.91 万元，调减金额 1,716.10 万元。 扣非归母净利润是投资者关注的重要指标，可能对公司经营业 绩和盈利能力的判断及投资者决策产生影响。公司结构性存款投资 收益调整认定为非经常性损益，导致公司 2022 年年报扣非归母净利 1 上 海 证 券 交 易 所 上证科创公监函〔2023〕0042 号 关于对湖北华强科技股份有限公司及有关责任 人予以监管警示的决定 当事人： 湖北华强科技股份有限公司，A 股证券简称：华强科技，A 股证 券 ...

Financial Performance - The company reported a net profit attributable to shareholders of RMB 72,433,635.82 for the year 2022, with a cash dividend payout ratio of 36.00%[5]. - The company's operating revenue for 2022 was ¥608.88 million, a decrease of 52.25% compared to ¥1.28 billion in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥72.43 million, down 77.38% from ¥320.22 million in 2021[24]. - The net profit after deducting non-recurring gains and losses was -¥8.56 million, a decline of 103.14% compared to ¥272.72 million in 2021[21]. - The cash flow from operating activities showed a net outflow of -¥181.30 million, a decrease of 138.38% from ¥472.43 million in 2021[24]. - The company's total assets at the end of 2022 were ¥5.17 billion, down 2.37% from ¥5.29 billion at the end of 2021[22]. - The net assets attributable to shareholders decreased slightly to ¥4.19 billion, a reduction of 0.97% from ¥4.23 billion in 2021[22]. - The basic earnings per share for 2022 were ¥0.21, down 83.06% from ¥1.24 in 2021[23]. - The gross profit margin for the main business was 16.61%, a decrease of 26.15 percentage points year-on-year[78]. - The revenue from military products decreased by 49.97% year-on-year due to delays in military procurement orders[80]. Dividend Distribution - As of December 31, 2022, the total distributable profit was RMB 258,899,381.89, with a proposed cash dividend of RMB 0.757 per share (before tax) based on a total share capital of 344,500,000 shares[5]. - The company plans to distribute a total cash dividend of RMB 26,078,650.00 (before tax) to shareholders[5]. - The company maintains a cash dividend policy that requires at least 20% of the distributable profits to be distributed as cash dividends, barring special circumstances[181]. - The company emphasizes a stable and continuous profit distribution policy, balancing investor returns with sustainable development[180]. - The board of directors is responsible for discussing and proposing the profit distribution plan, which must be approved by the shareholders' meeting[181]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 10.79%, up 6.17 percentage points from 4.62% in 2021[23]. - Total R&D investment reached ¥65,709,823.87, an increase of 11.52% compared to the previous year, with R&D expenses accounting for 10.79% of operating revenue, up from 4.62%[59]. - The company has developed 15 core technologies, including integrated design technology for respiratory devices and broad-spectrum protective materials against chemical agents[55]. - The company is committed to continuous R&D investment to maintain its competitive edge in the special protective equipment market, despite facing potential risks from insufficient R&D funding and market competition[75]. - The company is focusing on R&D for new technologies, with an investment of CNY 519,400 allocated to the technology committee[145]. Operational Risks and Governance - The company has outlined various operational risks and corresponding mitigation strategies in the report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[8]. - The company has not disclosed any special arrangements for corporate governance[6]. - The company has established a robust internal control system to enhance risk prevention capabilities and ensure compliance with regulations[137]. Market and Industry Trends - The company faced significant revenue declines due to delays in military equipment orders and a drop in domestic COVID-19 vaccine demand[24]. - The special protection equipment industry is experiencing rapid growth due to increasing defense budgets and the rising demand for advanced military equipment[44]. - The pharmaceutical packaging industry is expected to grow significantly due to rising disposable incomes, an aging population, and expanding health insurance coverage, creating opportunities for upstream pharmaceutical packaging materials[123]. - The competitive landscape in the defense industry is intensifying as the market access threshold for military products has been significantly lowered, allowing more enterprises to enter the sector[121]. Corporate Governance and Management - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and proper governance[135]. - The board of directors has convened seven meetings, maintaining independence and fulfilling its strategic decision-making responsibilities[136]. - The company has established specialized committees under the board, including Audit and Risk Management Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee[167]. - The company has not faced any significant issues regarding independence from its controlling shareholders[138]. - The company has not reported any significant changes in its board of directors or senior management during the reporting period[143]. Environmental and Social Responsibility - The company invested 1.9378 million yuan in environmental protection efforts during the reporting period[192]. - The company disposed of 1,155 tons of general industrial solid waste and 50.26 tons of hazardous waste in compliance with regulations[197]. - The company reduced carbon dioxide equivalent emissions by 418 tons through the implementation of carbon reduction technologies[199]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the upcoming quarter, driven by new product launches and market expansion strategies[146]. - The company plans to pursue strategic acquisitions to enhance its product portfolio and market presence[146]. - New product development is expected to contribute an additional CNY 200 million in revenue over the next fiscal year[146]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of up to 300 million for potential targets[152].